In recent years, due to the advent of sensitive instrumentation and methodologies, it has been possible to identify parameters that predict the quality of response of individual patients to treatments for specific selected diseases,
Youcef M. Rustum, PhD
Advertisement
Articles by Youcef M. Rustum, PhD
Most clinical drug regimens for irinotecan (CPT-11 [Camptosar]) have been empirically based on classic in vivo pharmacokinetic and pharmacodynamic considerations. We propose an alternative approach that attempts to
Advertisement
Latest Updated Articles
- Rational Design of Irinotecan Administration Based on Preclinical Models
Published: August 1st 1998 | Updated:
- Clinical Implications of 5-FU Modulation
Published: July 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
3
BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer
4
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
5
